← Back to Clinical Trials
Recruiting NCT03836248

NCT03836248 Study of the Contribution of Osteopathic Treatment to Classic Medical Management in Patients With Chronic Low Back Pain

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03836248
Status Recruiting
Phase
Sponsor Clinique Pasteur
Condition Chronic Low Back Pain
Study Type INTERVENTIONAL
Enrollment 199 participants
Start Date 2019-10-02
Primary Completion 2028-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 64 Years
Study Type INTERVENTIONAL
Interventions
Osteopathic treatmentSham osteopathic treatmentCurrent practice Medication treatment

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 199 participants in total. It began in 2019-10-02 with a primary completion date of 2028-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The management of chronic low back pain is now part of a multi-disciplinary set of proposals with the aim of adapting for each patient orientations of both medicated and non-medicated care. Very classically, analgesic treatment of stage I or II is of use, reinforced by the occasional use of NSAIDs in the absence of contraindication. In this medical attempt of the control of the pain associates a physical care (supervised exercises, physiotherapy care), cognitive and behavioral therapy, multidisciplinary care. Osteopathic treatment is a specific manual diagnostic and therapeutic procedure. This study aims to evaluate the relevance of providing osteopathic treatment in combination with classical medical treatment in the management of patients with chronic non-specific low back pain.

Eligibility Criteria

Inclusion Criteria: * Patient with chronic non-specific low back pain: degenerative lumbalgia and low back pain unrelated to anatomical lesions that have been evolving for more than 3 months. * Patient affiliated with a social security scheme or equivalent * Patient having signed the study informed consent form. Exclusion Criteria: * Patient with specific low back pain: patient with one of the following pathologies: degenerative neurological pathology; infectious pathology; fracture vertebral lesion less than 1 year; vertebral osteosynthesis material or canal narrowing. * Patient following a treatment of the Morphinic or Neuroleptic type. * Pregnant, breastfeeding or parturient woman * Patient participating in another clinical study * Protected patient: Major under some form of guardianship ; Hospitalized without consent

Contact & Investigator

Central Contact

Barthélémy De Truchis de Varennes, MD

✉ bdetruchis@clinique-pasteur.com

📞 + 33 5 62 21 35 36

Principal Investigator

Barthélémy De Truchis de Varennes, MD

PRINCIPAL INVESTIGATOR

Clinique Pasteur

Frequently Asked Questions

Who can join the NCT03836248 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 64 Years, studying Chronic Low Back Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03836248 currently recruiting?

Yes, NCT03836248 is actively recruiting participants. Contact the research team at bdetruchis@clinique-pasteur.com for enrollment information.

Where is the NCT03836248 trial being conducted?

This trial is being conducted at Toulouse, France.

Who is sponsoring the NCT03836248 clinical trial?

NCT03836248 is sponsored by Clinique Pasteur. The principal investigator is Barthélémy De Truchis de Varennes, MD at Clinique Pasteur. The trial plans to enroll 199 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology